Latest Breaking News On - All statutory interpretation issues were - Page 1 : comparemela.com

The first of three pending appeals on whether a pharmaceutical manufacturer can limit distribution of covered 340B drugs to contract pharmacies resulted in a clear victory for pharmaceutical manufacturers.

United statesDistrict of columbiaAstrazeneca pharmsEli lillyNovartis pharmaceuticals corpThird circuit rulesManufacturer restrictionsThird circuitAll statutory interpretation issues wereSeventh circuitPharmaceutical manufacturers340b drug pricing programLife sciencesFood and drugs lawLife sciencesIotechnology amp nanotechnology